Thursday, July 14, 2022
HomeNewsEU provides extreme allergic reactions as facet impact of Novavax COVID vaccine

EU provides extreme allergic reactions as facet impact of Novavax COVID vaccine


Article content material

The European Medicines Company on Thursday recognized extreme allergic reactions as potential uncomfortable side effects of Novavax Inc’s COVID-19 vaccine.

The vaccine was approved by U.S. regulators on Wednesday, and its product label in america warns towards administering the shot to individuals with a historical past of allergic reactions to any elements of the shot.

The EMA stated it will additionally replace the product data for the vaccine so as to add uncommon or decreased feeling within the pores and skin as a brand new facet impact.

Solely 250,000 doses of Novavax’s COVID vaccine, Nuvaxovid, have been administered in Europe thus far since its launch in December, in accordance with the European Centre for Illness Prevention and Management.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments